RACHEL CLARK: Open Payments
NPI 1255728648 · SALISBURY, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,810 in 89 payments from 21 companies in 2025. Trend: 2023 $591 · 2024 $1,807 · 2025 $1,810
Food & beverage: $1,710Education: $100
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $235 |
| Teva Pharmaceuticals USA, Inc. | 10 | $225 |
| Lundbeck LLC | 14 | $212 |
| E.R. Squibb & Sons, L.L.C. | 9 | $172 |
| Alkermes, Inc. | 7 | $153 |
| Otsuka America Pharmaceutical, Inc. | 7 | $138 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $123 |
| Vanda Pharmaceuticals Inc. | 4 | $108 |
| Neurocrine BioSciences, Inc. | 4 | $84 |
| Axsome Therapeutics, Inc. | 2 | $48 |
Products named: COBENFY, VRAYLAR, ABILIFY ASIMTUFII, REXULTI, ARISTADA, CAPLYTA, INGREZZA, ABILIFY MAINTENA.
Industry payments across MD — which companies pay providers there.
